News Merck & Co in pole position for Ebola vaccine approval as FD... The FDA is to review Merck & Co’s Ebola vaccine, giving the US pharma a chance to grab a first approval within six months.
News BMS' Opdivo misses target in aggressive brain cancer trial It’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Squibb’s PR team have had to issue news of another trial disappointment from the misfiring c
News AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ... AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.
News Merck & Co and others test vaccine delivery drone Merck & Co is among the partners behind a consortium testing the potential to deliver temperature-controlled medicines and vaccines using a drone.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.